Blog · Regulatory · Published 2026-08-09
FDA 503A Inspections: The Records a Pharmacy Should Be Able to Produce Immediately
During an FDA inspection of a 503A compounding pharmacy, investigators expect core records to be immediately producible — not reconstructed later. The working list: prescription records tying each compounded preparation to a patient-specific prescription; the master formulation record and the completed compounding record for each batch or preparation; ingredient records showing component identity, source, certificates of analysis, and receipt; equipment maintenance, calibration, and cleaning logs; personnel training and competency documentation; environmental and (for sterile work) air-quality monitoring records; beyond-use-date assignments with their basis; complaint and adverse-event files; and records of any product recalls or corrections. A pharmacy that maintains these as a matter of routine can hand them over the same day.
Why a patient should care about a pharmacy's paperwork
Records discipline is the closest thing compounding has to a quality signal you can reason about from outside. A compounded GLP-1 vial carries no FDA premarket review — the "not FDA approved" distinction is structural — so what stands between a prescription and a problem is the pharmacy's own system: formulation records that make each batch reproducible, ingredient records that make the API traceable, monitoring that makes sterility more than a hope, and complaint files that make problems visible. When FDA's Form 483 observations cite compounding pharmacies, missing or unproducible records are among the most common findings — and they are the findings most predictive of everything else.
How to use this list as a consumer
You will not be auditing anyone, but you can borrow the logic. Our pharmacy-verification workflow starts with getting the dispensing pharmacy's name from your program; from there, a state board license lookup and a search of FDA's warning-letter and inspection databases take minutes. If a pharmacy has been inspected, the public record often shows whether records issues appeared. And one direct question is fair game for any program: "Can your pharmacy provide a certificate of analysis for my batch?" — a small ask that tests the same machinery this whole list describes. Related reading: 503A vs 503B and how to read a warning letter.
Frequently asked questions
What records must a 503A pharmacy keep?
Core records include patient-specific prescriptions, master formulation and compounding records, ingredient/component records with certificates of analysis, equipment and cleaning logs, personnel training files, environmental monitoring for sterile work, beyond-use-date assignments, and complaint/adverse-event files.
What does 'immediately producible' mean in an FDA inspection?
That the record exists, is organized, and can be handed to the investigator during the inspection — not assembled afterward. Inability to produce core records is itself a common inspection observation.
Can patients see a pharmacy's inspection history?
Often, in part: FDA's warning-letter database is public and searchable, and inspection outcomes surface in public records. Our pharmacy-verification workflow walks the lookups step by step.
Primary sources
Regulatory statements in this article draw on FDA public materials: FDA — Human Drug Compounding; FDA — Warning Letters database; FDA — Inspection references.
Independent & transparent
Independently operated by US Peptides Partners LLC. Rankings are editorial, computed from published pricing under the methodology, and are not for sale. Outbound provider links carry referral-tracking tags; no arrangement changes a ranking — if a provider out-scores the current leader on captured figures, the ranking changes.